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A B S T R A C T
Detoxification in hepatocytes is a strictly controlled process, in which the governed action of membrane
transporters involved in the uptake and efflux of potentially dangerous molecules has a crucial role. Major
transporters of hepatic clearance belong to the ABC (ATP Binding Cassette) and Solute Carrier (SLC) protein
families. Organic anion-transporting polypeptide OATP1B1 (encoded by the SLCO1B1 gene) is exclusively ex-
pressed in the sinusoidal membrane of hepatocytes, where it mediates the cellular uptake of bile acids, bilirubin,
and also that of various drugs. The removal of toxic molecules from hepatocytes to the bile is accomplished by
several ABC transporters, including P-glycoprotein (ABCB1), MRP2 (ABCC2) and BCRP (ABCG2). Owing to their
pharmacological relevance, monitoring drug interaction with OATP1B1/3 and ABC proteins is recommended.
Our aim was to assess the interaction of recently identified fluorescent OATP substrates (various dyes used in cell
viability assays, pyranine, Cascade Blue hydrazide (CB) and sulforhodamine 101 (SR101)) (Bakos et al., 2019;
Patik et al., 2018) with MRP2 and ABCG2 in order to find fluorescent probes for the simultaneous character-
ization of both uptake and efflux processes. Transport by MRP2 and ABCG2 was investigated in inside-out
membrane vesicles (IOVs) allowing a fast screen of the transport of membrane impermeable substrates by efflux
transporters. Next, transcellular transport of shared OATP and ABC transporter substrate dyes was evaluated in
MDCKII cells co-expressing OATP1B1 and MRP2 or ABCG2. Our results indicate that pyranine is a general
substrate of OATP1B1, OATP1B3 and OATP2B1, and we find that the dye Live/Dead Violet and CB are good
tools to investigate ABCG2 function in IOVs. Besides their suitability for MRP2 functional tests in the IOV setup,
pyranine, CB and SR101 are the first dual probes that can be used to simultaneously measure OATP1B1 and
MRP2 function in polarized cells by a fluorescent method.
1. Introduction
The liver has a central role in the defense of the body against
harmful compounds. Membrane transporters expressed in hepatocytes
are key players in the elimination of potentially toxic compounds of
endogenous or exogenous origin (Jetter and Kullak-Ublick, 2019). Na+-
and ATP-independent uptake of bile acids, bilirubin, steroid hormones
and several drugs from the blood into the liver is mediated by members
of the Organic anion-transporting polypeptides family, OATP1B1,
OATP1B3 and OATP2B1 (Dawson et al., 2009; Hagenbuch and
Stieger, 2013). Conversely, following metabolism by hepatic enzymes,
modified compounds are effluxed from hepatocytes into the bile or back
to the blood stream by the action of ABC (ATP Binding Cassette)
transporters including P-glycoprotein (ABCB1), MRPs (ABCC family)
and BCRP (ABCG2) (Kock and Brouwer, 2012). Coordinated action of
hepatic OATPs and ABCs ensures efficient hepatobiliary elimination of
their shared substrates.
OATP1B1, encoded by the SLCO1B1 gene is exclusively expressed in
the sinusoidal membrane of hepatocytes (Konig et al., 2000), and is the
most abundant OATP of the human liver (Badee et al., 2015; Kimoto
et al., 2012; Prasad et al., 2014). OATP1B1 is an organic anion ex-
changer that mediates the cellular uptake of bile acids, bilirubin,
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thyroid and sex hormones, and also that of numerous clinically applied
drugs (Roth et al., 2012). OATP1B1 is a site of drug-drug interactions
(DDIs), inhibition of its function results e.g. in statin-induced myopathy
(Link et al., 2008; Shitara, 2011; Shitara et al., 2003).
MRP2 (ABCC2) is expressed in the canalicular membrane of hepa-
tocytes (Jedlitschky et al., 2006) where it mediates the active efflux of
conjugated and unconjugated organic anions (e.g. bilirubin and steroid
conjugates), and also the co-transport of uncharged molecules with
glutathione into the bile (Konig et al., 1999). Mutations in OATP1B
(SLCO1B) or MRP2 (ABCC2) genes both lead to increased serum bilir-
ubin levels respectively termed as Rotor or Dubin Johnson syndrome,
indicating that bilirubin elimination through the liver requires the
function of OATP1B1/3 and MRP2 (van de Steeg et al., 2012)
(Konig et al., 1999). Besides its endogenous substrates, MRP2 also re-
cognizes various drugs (Jedlitschky et al., 2006). Hence, by mediating
the extrusion of metabolites from hepatocytes into the bile, MRP2 plays
a key role in the terminal phase of detoxification (Zhou et al., 2008).
Similarly to MRP2, BCRP (ABCG2) is also expressed in the canali-
cular membrane of hepatocytes (Horsey et al., 2016; Maliepaard et al.,
2001) and is involved in the hepatobiliary excretion of various organic
compounds (Hirano et al., 2005; Lee et al., 2015; Patel et al., 2016).
ABCG2 is a genuine multidrug transporter, recognizing a plethora of
chemically diverse molecules that includes chemotherapeutics, statins,
anti-HIV drugs and antibiotics (Doyle et al., 1998; Horsey et al., 2016).
Given its wide substrate recognition pattern, ABCG2 is also a site of DDI
(Lee et al., 2015; Mao and Unadkat, 2015). ABCG2 transports several
endogenous substrates such as urate, haem and estrogen conjugates
(estradiol-glucuronide and estrone sulfate) (Heyes et al., 2018). The
most common ABCG2 polymorphism c.421C>A (p.141Q>K,
rs2231142) is associated with gout, due to the mislocalization of the
protein (Matsuo et al., 2009; Woodward et al., 2009). Significantly,
SNPs in ABCG2 have been correlated with the altered pharmacokinetics
of statins and sulfasalazin (Giacomini and Huang, 2013; Heyes et al.,
2018). Thus, MRP2, ABCG2 and OATP1B1 have overlapping substrate
specificities. They are important determinants of hepatobiliary excre-
tion of various drugs, including chemotherapeutics, statins and anti-
HIV agents (Giacomini et al., 2010; Hooijberg et al., 1999;
Kitamura et al., 2008; Liu et al., 2010; Roth et al., 2012). Therefore co-
administration of their substrates can lead to serious side effects, un-
derlying the relevance of these transporters as sites of DDIs. Hence,
according to the recommendations of the US Food and Drug Adminis-
tration (FDA) and the European Medicines Agency (EMA), interactions
with OATP1B1/3 and ABCG2 (and also potentially with MRP2) should
be assayed during drug development. FDA and EMA regulations require
the use of sensitive and reliable functional assays for the evaluation of
transporter drug interactions (Giacomini et al., 2013).
Radioactively labeled substrates, such as bromosulphophtalein,
leukotriene C4, dehydroepiandrosterone sulfate (DHEAS), estrone-3-
sulfate (E1S) or estradiol-17β-D-glucuronide (E217G) have been re-
peatedly used for the characterization of OATP and ABC transporter
function and for the study of DDIs (Cui et al., 2001; Hirouchi et al.,
2009; Liu et al., 2006; Matsushima et al., 2005). In general, a limitation
of the radioligand transport assays is the cost associated with the
radiolabeling of the substrates. Fluorescence assays offer a cost effective
alternative, and it was shown that fluorescent probe substrates provide
an effective and sensitive means to investigate transporter function and
drug-transporter interactions (Szakacs et al., 2008). Since the discovery
of Calcein-AM to probe P-glycoprotein and MRP function more than
two decades ago (Hollo et al., 1994), the list of fluorescent MRP2
substrates has expanded (Cantz et al., 2000; Notenboom et al.,2005;
Prevoo et al., 2011; Siissalo et al., 2009). Similarly, fluorescent dye
substrates of ABCG2 (Hoechst, DyeCycle Violet) have long been used to
investigate its function or drug interactions (Mathew et al., 2009;
Ozvegy et al., 2002). Whereas the study of the efflux function of ABC
transporters requires the use of dyes that can accumulate in the cells
(high passive uptake) (Szakacs et al., 2008), ideal test substrates
measuring OATP function are cell impermeable (Bednarczyk, 2010;
Gui et al., 2010; Kovacsics et al., 2017; Patik et al., 2018;
Yamaguchi et al., 2006).
To date, fluorescent probes allowing the simultaneous investigation
of OATP1B1 and the hepatic ABC transporters have not been identified.
The goal of the current work was to analyze the interaction of fluor-
escent OATP1B1 substrates with MRP2 and ABCG2 in order to find dual
OATP ABC transporter probes. Our earlier work has identified Zombie
Violet (ZV), Live/Dead Violet (LDV), Live/Dead Green (LDG), Cascade
Blue hydrazide (CB), Alexa Fluor 405 (AF405) (Patik et al., 2018), and
recently SR101 (sulforhodamine 101) (Bakos et al., 2019) as novel
fluorescent substrates of OATP1Bs. We have also shown that CB and
AF405 can be applied as probes in OATP1B1/3 or OATP2B1 drug in-
teraction tests (Patik et al., 2018). Since these OATP probes are cell-
impermeant, their transport by ABCG2 or MRP2 cannot be directly
investigated in cellular assays. However, transporter-mediated accu-
mulation of the same dyes can be measured in inside-out vesicles
(IOVs). Because of the reverse orientation of the membrane lipid bilayer
and the efflux transporters, ATP-dependent uptake of a substrate into
IOVs corresponds to cellular efflux, allowing the measurement of the
transport of cell impermeable dyes by ABC efflux transporters. Using
this experimental setup, we show that several cell-impermeable fluor-
escent substrates are indeed transported by MRP2 and ABCG2. Theo-
retically, cellular efflux may be measured if the accumulation of the cell
impermeable dyes was facilitated by uptake transporters. Using double-
transfected, polarized MDCKII cells overexpressing OATP1B1 and
MRP2 or ABCG2, we identify dual OATP1B1 and MRP2 fluorescent
probes, setting the stage for a fluorescence-based assay development
measuring vectorial transport mediated by these transporters.
2. Materials and methods
2.1. Materials
Zombie Violet was purchased from BioLegend® (San Diego, CA, US).
LIVE/DEAD® Fixable Cell Stain Dyes (Violet and Green), fluorescein-
methotrexate and Cascade Blue hydrazide were purchased from
Thermo Fisher Scientific (Waltham, MA, US). All other materials, if not
indicated otherwise, were from Sigma Aldrich, Merck (Budapest, HU).
2.2. Generation of cell lines and cell culturing
A431 cells expressing OATPs 1B1, 1B3 or 2B1 and their mock
transfected counterparts were generated previously as described in
Patik et al. (2018). The MDCKII-MRP2 cell line was generated pre-
viously (Bakos et al., 2000). In order to generate MDCKII cells expres-
sing ABCG2, MDCKII parental cells were transfected with 1 µg plasmid
DNA (pSB-CMV-ABCG2, allowing transposon mediated genomic inser-
tion of ABCG2 cDNA (Saranko et al., 2013)) and 100 ng plasmid con-
taining the 100x Sleeping Beauty transposase using Lipofectamine
2000® reagent (Thermo Fisher Scientific) according to the re-
commendation of the manufacturer. After 48 hours the transfection
medium was removed and the cells were selected in puromycin (1 µg/
ml) for two weeks. Transfected cells were sorted based on labeling by
the anti-ABCG2 monoclonal antibody 5D3 (Bioscience), which binds to
a surface epitope (Ozvegy et al., 2002). Cells showing 5D3 positivity
were sorted using a BD FACSAria III Cell Sorter (BD Biosciences, San
Jose, CA, US).
OATP1B1 expression in MDCKII, MDCKII-MRP2 or MDCKII-ABCG2
cells was achieved by recombinant lentiviruses as described earlier
(Patik et al., 2018). Briefly, MDCKII parental, MDCKII-MRP2 and
MDCKII-ABCG2 cells were transfected with the pRRL-CMV-OATP1B1-
MCS-IRES-ΔCD4 vector. In order to generate mock transfected control
cells for transport experiments, MDCKII cells were transfected with the
pRRL-EF1-ΔCD4 vector. Transduced cells were sorted based on their
CD4 positivity using a BD FACSAria III Cell Sorter (BD Biosciences, San
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Jose, CA, US). OATP1B1 overexpressing cells were sorted based on their
increased Live/Dead Green uptake, as described earlier (Patik et al.,
2018).
A431 and MDCKII cells were grown in DMEM (Gibco, Thermo
Fisher Scientific (Waltham, MA, US)) completed with 10 % fetal bovine
serum, 2 mM L-glutamine, 100 U/ml penicillin, and 100 μg/ml strep-
tomycin at 37°C, 5% CO2, under sterile conditions.
2.3. Western blot
MDCKII cell lysates were separated on 7.5% Laemmli SDS-PAGE
gels and transferred onto PVDF membranes. Immunoblotting was per-
formed as described (Sarkadi et al., 1992). Membranes were incubated
overnight with anti-OATP1B1, anti-MRP2 (M2-I-4 / M2-III-6 mono-
clonal antibody) (Bakos et al., 2000) or anti-ABCG2 (BXP-21,
Maliepaard et al., 2001) antibodies or anti-β-actin antibody (A1978,
Sigma). The antibody used for the detection of OATP1B1 was a kind gift
from Dr. Bruno Stieger (Department of Clinical Pharmacology and
Toxicology, University Hospital, 8091 Zurich, Switzerland) (Kullak-
Ublick et al., 2001). Secondary antibodies were HRP-conjugated anti-
rabbit (OATP1B1) or anti-mouse (MRP2, ABCG2, ß-actin) antibodies
(Jackson ImmunoResearch, Suffolk, UK) in a dilution of 20,000x. Lu-
minescence was detected using the Luminor Enhancer Solution kit by
Thermo Scientific (Waltham, MA, US).
2.4. MRP2 and ABCG2 expression in insect cells and inside-out membrane
vesicle preparation
Recombinant baculovirus containing the ABCC2/MRP2 cDNA
(Bakos et al., 2000), ABCG2 cDNA (Ozvegy et al., 2002) or the cDNA of
an unrelated protein (Patik et al., 2015) were used to achieve transient
expression in Sf9 insect cells. Culturing and infection of Sf9 cells was
performed as described earlier (Sarkadi et al., 1992). Virus-infected Sf9
cells were harvested after 72 hours. Following washing with Tris-
mannitol buffer (50 mM Tris, pH 7.0, with HCl, 300 mM mannitol and
0.5 mM phenylmethylsulfonyl fluoride), cells were lysed and homo-
genized in TMEP (50 mM Tris, pH 7.0, with HCl, 50 mM mannitol, 2
mM EGTA, 10 µg/ml leupeptin, 8 µg/ml aprotinin, 0.5 mM phe-
nylmethylsulfonyl fluoride, and 2 mM dithiotreitol) using glass tissue
grinder tubes. Undisrupted cells were removed by centrifugation for 10
min at 500 g. Finally, the supernatant containing the membranes was
centrifuged for 1 h at 100 000 g, and the pellet was resuspended in
TMEP (with freshly appended 0.5 mM phenylmethylsulfonyl fluoride)
at concentration of 5-10 mg/ml. Membranes were stored at -80°C in
aliquots. (Bakos et al., 2000; Sarkadi et al., 1992). In the case of ABCG2
cholesterol enriched membranes IOVs were prepared in order to
achieve maximal ABCG2 activity (Telbisz et al., 2007). Cholesterol
loading was performed by incubation of the membranes (containing
ABCG2 or their controls) with TMEP containing 2 mM Cholesterol-
RAMEB (Cyclolab, Hungary) on ice for 30 minutes, prior to the final
centrifugation step (Telbisz et al., 2007).
2.5. Transport measurements in inside-out vesicles
Membrane vesicles (50 μg/tube) were incubated in transport buffer
(Bakos et al., 2000) with 4 mM MgATP or 4 mM MgAMP and with the
fluorescent dyes 1 μM sulforhodamine 101 (SR101)/fluorescein-meth-
otrexate (FMTX), 5 μM pyranine/Cascade Blue (CB), 10 μM Lucifer
Yellow (LY) or 0.2 μl/tube ZV/LDV/LDG for 10 (ZV/LDV/LDG/FMTX/
SR101/LY) / 20 (pyranine) / 30 (CB) minutes in 150 μl final volume at
37°C. These experimental conditions were evaluated by measuring
time- and concentration dependent transport of the fluorescent dyes in
preliminary experiments. For each compound, time and concentration
values yielding the highest signal/noise ratio measured were chosen.
Fig. 1. A) Structure of the dyes tested in the current study. B) Pyranine is a novel substrate of OATP1B1, OATP1B3 and OATP2B1. Concentration dependent uptake of
pyranine was measured in A431 cells overexpressing OATP1B1, OATP1B3 or OATP2B1, or mock transfected controls (Ctr.) seeded onto 96-well plates at 37°C in the
linear phase of transport, at 10 (OATP1B1) or 15 (OATP1B3 and OATP2B1) minutes at pH 5.5. Fluorescence was determined using an Enspire plate reader (Ex/Em:
403/517 nm). Transport kinetics was determined by subtracting fluorescence measured in mock transfected cells. Average +/- SD values of at least 3 independent
measurements are shown.
V. Székely, et al. European Journal of Pharmaceutical Sciences 151 (2020) 105395
3
When inhibition was investigated, the vesicles were pre-incubated with
1 μM Ko143, a known ABCG2 inhibitor (Allen et al., 2002) prior to the
addition of the fluorescent dyes. Reaction was stopped by the addition
of 550 μl ice cold transport buffer and by placing the samples on ice.
Eppendorf tubes were centrifuged for 5 min at 22000 g. Supernatant
was eliminated and the pellet was suspended in 200 μl RT (room
temperature) 1 x Phosphate Buffered Saline (PBS). The suspensions
were pipetted onto 96 well plates and fluorescence intensity was
measured in an Enspire Fluorescent plate reader (Perkin Elmer) at the
following wavelengths: 405/423 nm (ZV), 416/451 nm (LDV), 495/520
nm (LDG), 403/517 nm (pyranine), 400/419 nm (CB), 586/605 nm
(SR101), 428/540 nm (LY), 497/516 nm (FMTX). Transport activity in
the case of CB, pyranine, LY, SR101 and FMTX was determined based
on a calibration curve.
2.6. Transport measurements in MDCKII cells by flow cytometry
MDCKII cells were collected following trypsinization (0.2% trypsin)
in complete DMEM. After washing in 1 ml uptake buffer (125 mM NaCl,
4.8 mM KCl, 1.2 mM CaCl2, 1.2 mM KH2PO4, 12 mM MgSO4, 25 mM
MES, and 5.6 mM glucose, with the pH adjusted to 5.5/7.4 using 1 M
HEPES and 10 N NaOH for OATP/ABC function, respectively), 5 × 105
cells were incubated at 37°C for 10 min (calcein-AM (CaAM)) / 30 min
(CB, DCV (DyeCycle Violet)) in 100 µl fluorescent dye (final con-
centrations: 0.5 µM CaAM, 1-1 µM CB or DCV) diluted in the
appropriate buffer. CB/CaAM/DCV were used as substrates of
OATP1B1/MRP2/ABCG2 for validating functionality. The reaction was
stopped by the addition of 700 µl ice-cold 1 x PBS, and the samples
were kept on ice until the flow cytometry analysis. Cellular fluorescence
was determined of at least 20,000 living cells from each sample using
an Attune Acoustic Focusing Cytometer (Applied Biosystems, Life
Technologies, Carlsbad, CA, US).
2.7. OATP-mediated transport of pyranine using a microplate-based
transport assay
Uptake of pyranine in A431 cells overexpressing OATPs 1B1, 1B3 or
2B1 was measured as described previously (Patik et al., 2018). Briefly,
A431 cells (8 × 104/well) were seeded on 96-well plates in 200 μl
DMEM one day prior to the transport measurement. Next day the
medium was removed, and the cells were washed three times at room
temperature with 1 x Phosphate Buffered Saline (PBS). The cells were
pre-incubated with 50 μl uptake buffer (see above) at 37°C. The reac-
tion was started by the addition of 50 μl uptake buffer containing in-
creasing concentrations of pyranine. Cells were then incubated at 37°C
for 10 minutes (OATP1B1) or 15 minutes (OATP1B3 and OATP2B1).
The applied incubation time was evaluated during previous un-
published data. The reaction was stopped by removing the supernatant
and washing the cells three times with ice-cold 1 x PBS. Wells were
loaded with 200 μl ice-cold 1 x PBS and fluorescence was determined
Fig. 2. Fluorescent dye transport measurements in inside-out membrane vesicles. Uptake of the fluorescent dyes, ZV, LDV and LDG (0.2 μl/sample), 5 μM CB, 5 μM
pyranine, 1 μM SR101, 1 μM FMTX or 10 μM LY in MRP2- (panels A, B) or ABCG2- (panels C, D) containing or control membrane vesicles (50 μg) was measured for
30 minutes (CB), 20 minutes (pyranine) or 10 minutes (ZV, LDV, LDG, SR101, FMTX, LY) in the presence of 4 mM MgATP or 4 mM MgAMP at 37°C. Experiments
were repeated 3-times. Average of at least 3 independent replicates +/- SD are shown. Statistical significance was calculated between ATP-dependent signals. Delta
values generated by subtracting signals with MgAMP from that measured with MgATP were compared for statistical significance by Student's t-test, *: p< 0.05, **:
p< 0.01, ***: p<0.001.
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using an Enspire plate reader Ex/Em: 403/517 nm. OATP-dependent
transport was determined by extracting fluorescence measured in mock
transfected cells. Transport activity was calculated based on a calibra-
tion curve. Experiments were repeated in 3 biological replicates.
2.8. Transcellular transport measurements
For transcellular transport experiments, OATP1B1 and/or MRP2 or
ABCG2 overexpressing MDCKII cells (9 × 104 cells/insert) were grown
on Tissue culture plate inserts (6.5 mm diameter, 0.4 μM pore size,
VWR Ltd., Hungary) for four days. The cells were seeded in 300 μl
complete DMEM onto the insert membranes and 1 ml media was added
to the wells around the inserts in 24 well plates. The transport mea-
surement was started by the removal of the medium from the transwell
inserts and by washing the cells two times with 300 μl pH 7.4 uptake
buffer (see above). The wells were washed three times with 1 ml pH 5.5
uptake buffer (see above). After washing, 300 μl pH 7.4 buffer was
pipetted into the inserts containing the cells and 1 ml pH 5.5 buffer into
the wells and a 10 min pre-incubation period at 37°C was applied. The
reaction was started by the addition of 1 ml uptake buffer pH 5.5
(ensuring higher OATP1B1 transport (Patik et al., 2018)) containing
pyranine, CB, SR101, or FMTX (final concentrations 5-5 μM and 1-1 μM
respectively) to the wells, and the tissue culture plates were further
incubated at 37°C. When inhibitors were tested, 10 μM cyclosporin A
(CsA) or 40 μM benzbromarone was added to the lower or upper
compartment, respectively. To determine transport, 30 μl samples from
the upper compartment were collected every 5 minutes and pipetted
into 70 μl 1 x PBS for fluorescence measurements. In the case of
MDCKII-ABCG2-OATP1B1 cells, CB transport was determined at the
following time points: 0, 15 and 30 minutes. The fluorescence intensity
of the samples was determined using an Enspire plate reader (Perkin
Elmer) at the following wavelengths: 403/517 nm (pyranine), 400/419
nm (CB), 586/605 nm (SR101), or 497/516 nm (FMTX).
In order to evaluate the transport in the opposite direction (A-B),
transport reaction was started from the apical side by adding the sub-
strates at the same concentration as applied before but in 300 μl pH 7.4
buffer. Samples were collected from the wells (B side) to a 96 well plate,
100 μl at each time points until 25 minutes and fluorescence intensity
was determined as described before.
For evaluating intracellular accumulation of pyranine, transport
reaction in B-A direction was stopped after 30 minutes by removing the
solutions from the wells and inserts and washing the cells three times
with cold 1 x PBS on ice. Transwell inserts were then cut out and placed
into 200 μl 1% Triton-PBS in Eppendorf tubes. Inserts were incubated at
RT for 75 minutes, and then cell lysates were pipetted onto 96 well
plates. Fluorescence intensity was determined using an Enspire plate
reader as described above, Ex/Em: 403/517. In order to define the
amount of the dyes in the samples, a calibration curve was generated by
determining the fluorescence of increasing amounts of the given dye
dissolved in 200 μl 1 x PBS. We found that fluoresce of the dyes
Fig. 3. Expression and function of OATP1B1, MRP2 or ABCG2 in the MDCKII cell lines. 3A: 10 or 20 μg of total cell lysates were analyzed for transporter expression
by Western blot. Signals of OATP1B1/MRP2/ABCG2/ß-actin were visualized by the antibodies raised against these proteins. Transporter expression is equally present
for OATP1B1/MRP2/ABCG2 among the appropriate cell lines. ß-actin signals verified the equal amount of proteins in the samples tested. Experiments were repeated
at least 3-times. The result of one representative experiment is shown. 3B: Transporter function of OATP1B1, MRP2 or ABCG2 in MDCKII cell lines. Functionality of
the transporters OATP1B1, MRP2 or ABCG2 was determined based on the transport of CB, CaAM or DCV substrates, respectively. 5 × 105 MDCKII cells were
incubated at 37°C for 10 min (CaAM)/30 min (CB, DCV) in 100 µl fluorescent dye (final concentrations: 0.5 µM CaAM , 1-1 µM CB or DCV) diluted in the appropriate
buffer (pH 5.5/7.4 for OATP/ABC function). Cellular fluorescence was determined of at least 20,000 living cells from each sample using an Attune Acoustic Focusing
Cytometer (Applied Biosystems, Life Technologies, Carlsbad, CA, US). Transport measurements were repeated at least 3-times. One representative experiment is
shown. 3C: Transcellular transport of fluorescein-methotrexate: Basolateral to apical transcellular transport of FMTX (1µM) in MDCKII-OATP1B1, MDCKII-MRP2,
MDCKII-MRP2-OATP1B1 or control (Ctr., mock transfected) cells grown on transwell inserts for 4 days prior to the experiment was followed for 30 minutes at 37°C.
Average of 3 independent measurements +/- SD are shown.
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(pyranine, CB and SR101) diluted in PBS or accumulated in cells re-
mained stable even after 90 minutes of incubation at room temperature
(data not shown).
2.9. Data analysis and statistics
Kinetic parameters shown in Fig. 1B of dye uptake were analyzed by
Hill1 fit using the OriginPro 8 software (GraphPad, La Jolla, CA, USA).
Statistical significance was calculated by Student's t-test between ATP-
dependent signals. Delta values were generated by subtraction of
MgAMP or MgAMP+Ko signals from MgATP or MgATP+Ko signals,
respectively. These delta values were compared for statistical sig-
nificance by Student's t-test, *: p< 0.05, **: p< 0.01, ***: p< 0.001
(Figs. 2, 6).
Statistical analysis of the samples shown in Fig. 4B for multi com-
parison was evaluated by Tukey-Kramer HSD (Honest Significant
Differences) procedure, as a post-hoc test, after rejecting H0 in One-Way
ANOVA (α=0.05). Samples marked with the same letter (“a” for MRP2
and Ctr.) were not significantly different from each other.
3. Results
3.1. Pyranine is a novel substrate of hepatic OATPs, 1B1, 1B3 and 2B1
To expand the scope of fluorescent OATP substrates, we evaluated
the interaction of pyranine (HPTS, Solvent Green 7, trisodium 8-hy-
droxypyrene-1,3,6-trisulfonate), a pH indicator closely related to
Cascade Blue hydrazide (CB) (Avnir and Barenholz, 2005; Clement and
Gould, 1981; Gan et al., 1998) (Fig. 1) with OATP1B1, OATP1B3 and
OATP2B1. Measurements were carried out using A431 cells over-
expressing OATP1B1, OATP1B3 or OATP2B1. Whereas pyranine does
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Fig. 4. Transcellular transport of pyranine. 4A: Basolateral to apical transport of pyranine (5 μM) in MDCKII-OATP1B1, MDCKII-MRP2, MDCKII-MRP2-OATP1B1 or
control (Ctr., mock transfected) cells grown on transwell inserts for 4 days prior to the experiment was followed for 30 minutes at 37°C. Average of 5 independent
measurements +/- SD are shown. 4B: Intracellular levels of pyranine were determined in MDCKII cells after 30 minutes of incubation with 5 μM pyranine ad-
ministered from the basolateral side of the transwells. Average of 3 independent measurements +/- SD are shown. Statistical analysis for multi comparison was
evaluated by Tukey-Kramer HSD (Honest Significant Differences) procedure, as a post-hoc test, after rejecting H0 in One-Way ANOVA (α=0,05). Means +/- SD
marked with the same letter (“a” for Ctr. and MRP2) were not significantly different (p > 0.05, Tukey-Kramer HSD test) from each other unlike “b” and “c” which
mean significant difference. 4C: Lack of apical to basolateral transport of pyranine. Experiments were performed with pyranine (5 μM) added either to the apical or
the basolateral compartment and samples were taken from the basolateral (A-B) or the apical compartment (B-A), respectively until 25 minutes. Average of 3
independent measurements +/- SD are shown. 4D: Inhibition of pyranine transcellular transport by cyclosporin A (CsA) or benzbromarone (Benz). Transcellular (B-
A) transport of 5 μM pyranine can be inhibited by known OATP1B1 and MRP2 inhibitors, CsA and Benz. Vectorial transport was measured as described at Fig. 4A,
except that 10 μM CsA or 40 μM benzbromarone was added to the basolateral or apical compartment, respectively prior to the addition of pyranine (5 μM).
Fluorescence of pyranine was measured using an Enspire plate reader at Ex/Em 403/517 nm. Data obtained from 3 independent experiments +/- SD values are
presented as a percent of transport measured in MDCKII-MRP2-OATP1B1 cells without any inhibitor (NT).
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found a typical OATP-mediated uptake in A431 cells expressing a he-
patic OATP (Fig. 1B) revealing that pyranine is a common substrate of
these uptake transporters.
3.2. Identification of novel common fluorescent substrates of OATP1B1,
MRP2 and ABCG2
Hepatic OATPs and MRP2 or ABCG2 have an overlapping substrate
recognition profile (Giacomini et al., 2010). To characterize the sus-
ceptibility of fluorescent OATP probes to MRP2 or ABCG2 mediated
transport, we used inside-out membrane vesicles prepared from Sf9
(Spodoptera frugiperda) cells overexpressing either MRP2 or ABCG2
(Fig. 2). IOVs allow the investigation of the transport of membrane
impermeable substrates by efflux transporters that otherwise, in the
lack of passive uptake, could not be investigated in cell-based assays
with single transfectants. IOVs prepared from mock transfected Sf9
cells, as well as transport in the presence of MgAMP served as negative
controls for transport experiments. On the other hand, Lucifer Yellow
(LY) and fluorescein-methotrexate (FMTX), documented substrates of
ABCG2 or MRP2 (Deng et al., 2016; Notenboom et al., 2005;
Prevoo et al., 2011; Sjostedt et al., 2017), respectively, were used as
positive controls. As shown in Fig. 2A and B, ATP-dependent transport
by MRP2 was observed for FMTX, ZV, LDG, CB, SR101 and pyranine,
while LDV was not transported. Although uptake of the known sub-
strate LY indicated functionality of ABCG2, transport of ZV, LDG, pyr-
anine or SR101 by ABCG2 was not detected. On the other hand, we
observed significant transport of LDV and a weak transport of CB by
ABCG2. A weak ATP-dependent transport of SR101 was also present in
control vesicles (Fig. 2B and D). To reveal the nature of the SR101
uptake observed in control vesicles, transport was measured using
EDTA as a Mg2+ chelator or Na-orthovanadate as a general ATP-ase
inhibitor. These experiments showed a Mg2+-dependent and Na-or-
thovanadate sensitive transport of SR101, confirming the involvement
of a yet undefined insect transporter in SR101 transport (Supplemen-
tary Figure S1).
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Fig. 5. Transcellular transport of Cascade Blue hydrazide or sulforhodamine 101. Basolateral to apical transport of CB (5 μM, panel A) or SR101 (1 μM, panel B) in
MDCKII-OATP1B1, MDCKII-MRP2, MDCKII-MRP2-OATP1B1, MDCKII-ABCG2-OATP1B1 (panel A) or control (Ctr., mock transfected) cells grown on transwell inserts
for 4 days prior to the measurement was followed for 30 minutes at 37°C. Average of 4 independent measurements +/- SD are shown for MDCKII-OATP1B1, MDCKII-
MRP2, MDCKII-MRP2-OATP1B1 and Ctr. cells on panel A, and average of 3 independent measurements +/- SD are shown for MDCKII-ABCG2-OATP1B1 cells (panel
A) and on panel B. 5C: Lack of apical to basolateral (A-B) transport of the fluorescent dyes. Experiment was performed on MDCKII cells grown on transwell inserts for
4 days prior to the measurement. CB (5 μM) or SR101 (1 μM) were added to the apical (A-B transport) or basolateral (B-A transport) compartment and after 25
minutes of incubation at 37°C samples were taken from the basolateral (A-B transport) or apical (B-A transport) compartment, and fluorescence was determined. Data
are shown as a percent of B-A transport measured in MDCKII-MRP2-OATP1B1 cells. Average of 3 independent measurements +/- SD are shown. 5D: Inhibition of CB
or SR101 transcellular transport. Transcellular (B-A) transport of 5 μM CB or 1 μM SR101 can be inhibited by known OATP1B1 and MRP2 inhibitors, cyclosporin A
(CsA) and benzbromarone (Benz). Vectorial transport was measured as described at Fig. 4A, except that 10 μM CsA or 40 μM benzbromarone was added to the
basolateral or apical compartment, respectively prior to the addition of the dyes 5 μM CB or 1 μM SR101. Data represent average +/- SD values of 3 independent
experiments and are presented as a percent compared to the B-A transport measured in MDCKII-MRP2-OATP1B1 cells (NT).
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3.3. Transcellular transport of pyranine, a novel common substrate of
OATP1B1 and MRP2
In order to test whether the newly identified dual fluorescent sub-
strates can indeed be applied for the simultaneous investigation of
OATP1B1 and MRP2 function, we examined their transport in double
transfected polarized MDCKII cells. Since the structure of ZV, LDG and
LDV is unknown, these dyes were excluded from further experiments.
First, stable MDCKII cell lines co-expressing these transporters, termed
as MDCKII-MRP2-OATP1B1 or MDCKII-ABCG2-OATP1B1 were en-
gineered (see 2.2.). Cell lines containing solely OATP1B1, MRP2,
ABCG2 or mock transfected cells (MDCKII-1B1, MDCKII-MRP2,
MDCKII-ABCG2 or MDCKII-Ctr.) served as controls. Expression was
confirmed by Western blot analysis (Fig. 3A), and functionality of the
transporters was verified by transport assays using known OATP1B1,
MRP2 or ABCG2 substrates, CB, CaAM and DCV, respectively (Fig. 3B).
For transcellular transport measurements, MDCKII cells were grown
on transwell inserts for 4 days to reach a polarized state, when
OATP1B1 is localized to the basolateral membrane, and MRP2 or
ABCG2 are found apically (Cui et al., 2001; Matsushima et al., 2005).
First, FMTX, a previously identified substrate of OATP1B1 (Gui et al.,
2010) and MRP2 (Notenboom et al., 2005; Prevoo et al., 2011) was
used for the setup of the transcellular transport measurement. As shown
on Fig. 3C, a time-dependent transcellular basolateral to apical (B-A)
transport of FMTX could be observed in MRP2-OATP1B1 double
transfectants that was not present in the control, single transfected
MDCKII-1B1, MDCKII-MRP2 or MDCKII-Ctr. (mock) cells. Next, trans-
cellular transport of pyranine was determined. As shown on Fig. 4A, a
time-dependent B-A transport of pyranine could be observed in MRP2-
OATP1B1 double transfectants, and there was no B-A transport in single
or mock transfected cells. When intracellular accumulation of pyranine
was measured, we found that pyranine cannot enter the cells without
the function of OATP1B1, hence it cannot be detected in control or
MRP2 single transfected cells (Fig. 4B). To exclude leakage of the cell
monolayer, concurrent pyranine transport in the apical to basolateral
(A–B) direction was investigated. Transport of pyranine in both direc-
tions was measured on the MRP2-OATP1B1 double and OATP1B1
single transfectant cells (Fig. 4C). We found negligible transcellular
transport from the apical to the basal compartment in both cell lines.
These results indicate that the B to A directed transport is indeed de-
rived from the interaction of the dye with the OATP1B1 and MRP2
transporters. Finally, in order to verify that the increasing fluorescent
pyranine signal at the A side of double transfected cells is a result of the
concerted action of OATP1B1 and MRP2, the experiments were re-
peated in the presence of transporter inhibitors (Fig. 4D). Double
transfected cells treated with either cyclosporin A at the basal side or
benzbromarone at the apical side showed no detectable transcellular
transport. To control these experiments, OATP1B1 and MRP2 single
transfected cells were also treated with cyclosporin A or benz-
bromarone, at the basal or apical side, respectively. Taken together, the
results were consistent with the transcellular transport of pyranine in
double transfectants as a result of OATP1B1-mediated uptake and
MRP2-mediated efflux.
3.4. Identification of Cascade Blue hydrazide and sulforhodamine 101 as
dual OATP1B1 and MRP2 probes in transwell measurements
Based on the experiments evaluated in the Sf9 IOV assay, SR101 is
another potential common substrate of OATP1B1 and MRP2, and a
weak accumulation of CB in IOVs with MRP2 or ABCG2 was also de-
tected. Therefore, in order to test their applicability as fluorescent
probes in vectorial transport measurements, their transcellular trans-
port was investigated in transwell transport assays (Fig. 5). When fol-
lowing time dependent accumulation of CB or SR101 in the apical
compartment of the transwells, vectorial transport in MRP2-OATP1B1
double transfected cells was detected for both substrates (Fig. 5A-B).
Interestingly, although we detected ABCG2-mediated transport of CB in
IOVs, transcellular transport activity in ABCG2-OATP1B1 cells could
not be observed (Fig. 5A). Transcellular transport of CB and SR101 in
the A-B direction was negligible (Fig. 5C), and inhibitory measurements
performed with these dyes also confirmed OATP1B1- and MRP2-
mediated transport of CB and SR101 (Fig. 5D).
4. Discussion
Concerted action of hepatic uptake (OATP) and efflux transporters
(ABCC2 and ABCG2) is crucial in pharmacokinetics and in the dis-
position of therapeutic drugs and endogenous substances.
Consequently, simultaneous administration of transporter substrates
can lead to altered pharmacokinetics and undesired side effects.
Therefore, international regulations require the evaluation of
OATP1B1/3 and ABCG2 (and also potentially MRP2) during early










































Fig. 6. Inhibition of LDV (panel A) or CB (panel B) uptake in IOVs containing ABCG2. Membrane vesicles (50 μg) were incubated in the presence or absence of 1 μM
Ko143 for 5 minutes at 37°C. Transport reaction was started by the addition of 0.2 μl LDV/tube or 5 μM CB. Fluorescence after 10 minutes (LDV) or 30 minutes (CB)
of incubation was determined using an Enspire plate reader. Experiments were repeated 3-times. Average +/- SD values are shown. Statistical significance was
calculated between ATP-dependent signals. Delta values generated by subtracting MgAMP or MgAMP+Ko signal from the signal of MgATP or MgATP+Ko, re-
spectively were compared for statistical significance by Student's t-test, *: p< 0.05.
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phases of drug development.
Polarized cell lines engineered to overexpress both uptake and ef-
flux transporters are an accepted in vitro model of transepithelial
transport measurements. MDCKII cells co-expressing OATP1B and
MRP2 or OATP1B and ABCG2 have been used in numerous studies for
the measurement of vectorial transport of common OATP and ABC
transporter substrates (Cui et al., 2001; Fahrmayr et al., 2012;
Matsushima et al., 2005). Double-transfected cell lines allow the iden-
tification of dual substrates (especially when the test compound cannot
enter the cells without the contribution of an uptake transporter) and
also the determination of the involvement of transporters in the
transcellular transport (Matsushima, 2005; Sasaki, 2002). MDCKII cells
co-expressing OATP and ABC transporters are also used to investigate
DDIs mediated by these transporters (Cui et al., 2001; Fahrmayr et al.,
2012; Liu et al., 2006; Matsushima et al., 2005).
Considering their overlapping substrate specificities, OATP1Bs,
MRP2 and ABCG2 may also share common fluorescent substrates.
Indeed, several mutual fluorescent probes were reported (e.g. FMTX
Gui et al., 2010; Notenboom et al., 2005), cholyl-lysyl-fluorescein
(Barber et al., 2015; de Waart et al., 2010) or carboxy-dichloro-fluor-
escein derivatives (Heredi-Szabo et al., 2008)). Although separate stu-
dies have identified common fluorescent substrates of MRP2 and
OATP1Bs, these were not tested in double transfectants for vectorial
transport. The only exception is Fluo-3 that has been used in transcel-
lular transport experiments to investigate MRP2 and OATP1B3 function
(Cui et al., 2001). However, Fluo-3 is not transported by the major
hepatic OATP, OATP1B1 (Izumi et al., 2016), and application of
fluorescent probes for dual investigation of ABCG2 and OATP1B func-
tion have not yet been documented. One crucial difference between an
ideal probe substrate of uptake or efflux transporters is membrane
permeability. Uptake transporters require substrates with low mem-
brane permeability, while optimal efflux transporter substrates have
high levels of passive uptake (at least in measurements performed on
intact cells) (Bednarczyk, 2010; Gui et al., 2010; Kovacsics et al., 2017;
Patik et al., 2018; Szakacs et al., 2008; Yamaguchi et al., 2006).
However, shared substrates of uptake and efflux transporters can be
identified using double transfected polarized cells, or in transport ex-
periments using IOVs. IOVs allow the measurement of intravesicular
accumulation of cell impermeable dyes by inversely oriented efflux
transporters, and represent a faster and cheaper screening method
compared to the transcellular transport assay. Hence, in our current
work, the initial transport screens of the previously identified cell im-
permeable fluorescent OATP probes, and the novel dye substrate pyr-
anine (Fig. 1B), were performed on IOVs containing MRP2 or ABCG2.
First, in order to find an alternative for CB, we tested pyranine for
transport by hepatic OATPs (Fig. 1B). We found that although pyranine
is a lower affinity substrate compared to CB (pyranine Km values for
OATP1B1, OATP1B3 and OATP2B1 were 27.8, 92.2 and 65.6 μM, re-
spectively, vs. CB Km values were 2.6, 21 and 21 μM (Patik, 2018)), its
transport by all three OATPs is about 3-times higher than that of CB.
Therefore, we conclude that pyranine can be an excellent tool to in-
vestigate hepatic OATP function.
The IOV-based transport screen identified the hitherto undescribed
transport of ZV, LDG, pyranine, SR101 and CB by MRP2, and LDV and
CB transport by ABCG2 (Fig. 2). Interestingly, SR101 has been pre-
viously identified as a transported substrate of an MRP-like fish and rat
transporter (Miller et al., 2002, 2000). However, direct interaction of
this dye with human MRP2 has not yet been documented. After the IOV
screen, the novel substrates were tested in OATP1B1-MRP2 double
transfected MDCKII cells for basolateral to apical transport, which
confirmed pyranine, CB and SR101 as dual probes of OATP1B1 and
MRP2 (Figs. 4 and 5). In these experiments fluorescein-methotrexate, a
previously identified substrate of both OATP1B1 and MRP2 served as
positive control (Gui et al., 2010; Notenboom et al., 2005). Vectorial
transport could be inhibited by known OATP MRP2 inhibitors, in-
dicating that these fluorescent probes can be used for assessing drug
interactions with OATP1B or MRP2.
Although CB transport was very low in MRP2 and ABCG2 con-
taining IOVs, we still detected significant transport of this dye in double
transfected MDCKII-MRP2-OATP1B1 cells. However, although expres-
sion and function of both OATP1B1 and ABCG2 was confirmed in the
double transfected MDCKII cell line (Fig. 3A-B), we could not detect any
transcellular transport of CB (Fig. 5A). These discrepancies can be ex-
plained by the conversion of CB in the cells (but not in IOVs) into a
metabolite that is a higher affinity substrate of MRP2 than CB, but not
recognized anymore by ABCG2. Mass spectrometry studies analyzing
CB extruded from MDCKII-MRP2-OATP1B1 cells may clarify this issue.
These results underline the relevance of cell-based assays, which are
influenced by the intracellular metabolism of compounds that are also
relevant in physiological drug transporter and drug-drug interactions.
Finally, since dual probes of OATP1B1 and ABCG2 suitable for
transcellular transport measurements have not been identified, we also
tested the transport of LDV, identified here as a substrate for ABCG2
(Fig. 2C). However, these experiments also failed to detect any vectorial
transport in MDCKII-ABCG2-OATP1B1 cells (not shown). In addition, as
LY has been described as a substrate of zebrafish drOatp1d1
(Faltermann et al., 2016), and our IOV experiments (Fig. 2D) showed
high level of uptake of this compound by ABCG2, we tested LY trans-
port in MDCKII-OATP1B1 cells. However, we found no detectable
OATP1B1-mediated uptake of this compound (not shown), therefore LY
was also excluded as a dual OATP1B1/ABCG2 probe. Although our
efforts failed to set up an assay for vectorial transport of potential dual
OATP1B1 and ABCG2 probes, LDV and CB can still be used to detect
ABCG2 drug interactions in vesicular transport studies. As demon-
strated in Fig. 6, uptake of these dyes in IOVs is inhibited in the pre-
sence of Ko143, a specific ABCG2 inhibitor (Fig. 6).
Although cell lines engineered to overexpress pairs of uptake and
efflux transporter or even metabolic enzymes are an accepted model of
in vitro drug interaction screens, to recapitulate in vivo conditions more
complex models, e.g. human derived hepatocytes are needed. The dual
OATP MRP2 substrates identified in our study are good candidates to
monitor the function and drug interactions of these transporters in
hepatocytes. Due to their low passive permeability, practically no up-
take of pyranine, CB or SR101 is observed in mock transfected cells
(Fig. 1B, and see also in Bakos et al., 2019; Patik et al., 2018), pre-
dicting low unspecific labeling in cellular assays/experiments. On the
other hand, a plethora of transporters is present in hepatocytes, some of
which may be involved in the uptake or efflux of these dyes. Based on
our experiments, ABCG2 will not influence elimination of these dyes
from the cells. In addition, based on our preliminary experiments per-
formed with IOVs containing human ABCB1 (P-gp), no interaction with
pyranine, CB or SR101 can be expected (not shown). However, it
cannot be excluded that other ABC transporters, e.g. MRP3 (ABCC3),
MRP4 (ABCC4), expressed in the sinusoidal membranes of hepatocytes,
recognize these dyes and will limit their cellular accumulation. Simi-
larly, the interaction of the fluorescent dyes with other solute carriers
(SLCs) cannot be excluded. Future work will address the applicability of
the fluorescence assays in more complex models. For example, toxicity
of the test substrates may limit the applicability of these dyes in he-
patocytes. However, when we investigated this issue in MDCKII cells we
found no significant toxicity (Supplementary Fig. S2).
In conclusion we identify dual OATP1B1 MRP2 fluorescent probes,
and also novel fluorescent substrates of ABCG2. To our best knowledge,
pyranine, CB and SR101 are the first dual probes that can be applied for
determining in a single, fluorescence-based assay the activity of
OATP1B1 and MRP2 and for evaluating the DDI potential of drug
candidates.
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